Ixekizumab Associated New-Onset Inflammatory Bowel Disease

Ixekizumab is a monoclonal antibody targeting interleukin-17 approved for the treatment of psoriasis. In a recent post hoc meta-analysis of Phase-I to Phase-III clinical trials of anti-interleukin-17 agents for the treatment of plaque psoriasis, there was a rare association (<1%) with induction o...

Descripción completa

Detalles Bibliográficos
Autores principales: Nazarian, Amir, Grin, Andrea, Wijeratne, Don Thiwanka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209798/
https://www.ncbi.nlm.nih.gov/pubmed/32440523
http://dx.doi.org/10.14309/crj.0000000000000316
_version_ 1783531158653370368
author Nazarian, Amir
Grin, Andrea
Wijeratne, Don Thiwanka
author_facet Nazarian, Amir
Grin, Andrea
Wijeratne, Don Thiwanka
author_sort Nazarian, Amir
collection PubMed
description Ixekizumab is a monoclonal antibody targeting interleukin-17 approved for the treatment of psoriasis. In a recent post hoc meta-analysis of Phase-I to Phase-III clinical trials of anti-interleukin-17 agents for the treatment of plaque psoriasis, there was a rare association (<1%) with induction or exacerbation of inflammatory bowel disease. We report a case of new-onset ileal Crohn's disease in a 48-year-old woman on ixekizumab for psoriasis.
format Online
Article
Text
id pubmed-7209798
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer
record_format MEDLINE/PubMed
spelling pubmed-72097982020-05-21 Ixekizumab Associated New-Onset Inflammatory Bowel Disease Nazarian, Amir Grin, Andrea Wijeratne, Don Thiwanka ACG Case Rep J Case Report Ixekizumab is a monoclonal antibody targeting interleukin-17 approved for the treatment of psoriasis. In a recent post hoc meta-analysis of Phase-I to Phase-III clinical trials of anti-interleukin-17 agents for the treatment of plaque psoriasis, there was a rare association (<1%) with induction or exacerbation of inflammatory bowel disease. We report a case of new-onset ileal Crohn's disease in a 48-year-old woman on ixekizumab for psoriasis. Wolters Kluwer 2020-03-02 /pmc/articles/PMC7209798/ /pubmed/32440523 http://dx.doi.org/10.14309/crj.0000000000000316 Text en © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Case Report
Nazarian, Amir
Grin, Andrea
Wijeratne, Don Thiwanka
Ixekizumab Associated New-Onset Inflammatory Bowel Disease
title Ixekizumab Associated New-Onset Inflammatory Bowel Disease
title_full Ixekizumab Associated New-Onset Inflammatory Bowel Disease
title_fullStr Ixekizumab Associated New-Onset Inflammatory Bowel Disease
title_full_unstemmed Ixekizumab Associated New-Onset Inflammatory Bowel Disease
title_short Ixekizumab Associated New-Onset Inflammatory Bowel Disease
title_sort ixekizumab associated new-onset inflammatory bowel disease
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209798/
https://www.ncbi.nlm.nih.gov/pubmed/32440523
http://dx.doi.org/10.14309/crj.0000000000000316
work_keys_str_mv AT nazarianamir ixekizumabassociatednewonsetinflammatoryboweldisease
AT grinandrea ixekizumabassociatednewonsetinflammatoryboweldisease
AT wijeratnedonthiwanka ixekizumabassociatednewonsetinflammatoryboweldisease

Ejemplares similares